Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting

Mocini, David; Staibano, M; Mele, Luca; Giannantoni, Paride; Menichella, G; Colivicchi, Furio; Sordini, Paolo; Salera, P; Tubaro, Marco; Santini, Massimo

doi:10.1016/j.ahj.2005.02.001

Cited by 96 publications

(52 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clearly, our most interesting finding was the unexpectedly low mortality when compared to the expected rate described for these patients. The expected yearly mortality rate in patients with NYHA functional class III or higher, ranges between 20 and 30% [11]; in our study, 15 out of 15 patients in group A finished the 6-month follow up period of the study.…”

Section: Discussionmentioning

confidence: 96%

“…Furthermore, it has shown that ABM-MNCs isolated from those patients have a significantly reduced migratory and colony-forming activity in vitro and a reduced neovascularization capacity in vivo despite similar content of hematopoietic stem cells [16]. Different cellular implantation techniques have been performed including transepicardial [1,[9][10][11][12], selective intracoronary infusion [2][3][4] percutaneous transfemoral endoventricular [5,6] or coronary venous routes [8]. Each of these delivery methods has its distinct advantages and limitations and no single approach has gained favor as the optimal technique for cell transplantation.…”

Section: Discussionmentioning

confidence: 99%

“…Stem cell therapy may represent the hope for those types of patients [1][2][3][4][5][6][7][8][9][10][11][12]. Several studies discussed this promising therapy with different techniques and routes including surgical transepicardial (intramyocardial injection) [1,[9][10][11][12], selective intracoronary artery infusion [2][3][4], percutaneous transfemoral endoventricular (catheter-based transendocardial injection) [5,6] or retrograde coronary venous [8]. Here in, we aimed to assess the usefulness of intra-myocardial autologous stem cell injection as a hybrid procedure with CABG compared to conventional CABG only in those patients with ischemic heart disease with non-viable or non-graftable myocardial segments.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Stem Cell Therapy Combined with Myocardial Revascularization: A Pilot Study using the Harvest Technique

Mostafa¹

2016

JCCR

View full text Add to dashboard Cite

DesignThis is a prospective, randomized double-armed (controlled) clinical trial. Participants:Thirty ischemic heart patients who were already scheduled for first-time isolated CABG with either nonviable or ungraftable myocardial segments, which was not suitable for conventional forms of revascularization. There were 27 males and 3 females (their ages ranged between 44 to 74 years old with a mean of 58.77). AbstractBackground: To assess the usefulness of intra-myocardial autologous stem cell injection as a hybrid procedure with coronary artery bypass grafting (CABG) compared to conventional CABG only in the patients with ischemic heart disease with non-viable or non-graftable myocardial segments.Methods: After approval of Local Ethics Committee and obtaining written informed consent, a prospective, comparative randomized study was conducted on 30 ischemic heart patients with non-viable or non-graftable segments. They were divided into two groups. Group A (15 patients): where intra myocardial injection of autologous bone marrow mononuclear cells (ABM-MNCs) was done in conjunction with CABG. Group B (15 patients): where CABG was performed only. Resting and stress echocardiography follow up was done for 6 months.Results: There was no mortality in either group. No complications were noted at a mean of 6 months after surgery. Group A showed a significant improvement (mean of 7.25% and P<0.001) in left ventricular ejection fraction (LVEF). Both end-diastolic (LVEDD) and end-systolic (LVESD) diameters showed significant decrease compared to pre-operative values. LVEDD decreased by a mean of 5.23 (P <0.001) while LVESD by a mean of4.21 (P<0.001). Conclusion:Stem cell therapy combined with CABG improves cardiac function compared with revascularization alone. In the same time, it is safe, feasible, and reproducible and doesn't increase the risk of major adverse events or mortality.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Stem Cell Therapy Combined with Myocardial Revascularization: A Pilot Study using the Harvest Technique

Mostafa¹

2016

JCCR

View full text Add to dashboard Cite

show abstract

“…Although some trials failed to demonstrate a significant increase in cardiac function after cell transplantation when compared with controls, several other randomized trials showed measurable improvements that were comparable to established therapeutic regimes (Reffelmann et al, 2009). Nonrandomized, smaller-scale trials also produced variable results, ranging from no significant changes in left ventricular ejection fraction to a significant improvement, of up to a 14% increase, during the follow-up period (Strauer et al, 2002;Perin et al, 2004;Fernandez-Aviles et al, 2004;Ince et al, 2004;Strauer et al, 2005;Katritsis et al, 2005;Bartunek et al, 2005;Mocini et al, 2006;Gavira et al, 2006;Ahmadi et al, 2007;Choi et al, 2007;Klein et al, 2007;Li et al, 2007;Stamm et al, 2007;Tatsumi et al, 2007).…”

Section: Clinical Studiesmentioning

confidence: 99%

Cardiac repair and regeneration: the Rubik’s cube of cell therapy for heart disease

Boudoulas

Hatzopoulos

2009

Disease Models &Amp; Mechanisms

View full text Add to dashboard Cite

Acute ischemic injury and chronic cardiomyopathies damage healthy heart tissue. Dead cells are gradually replaced by a fibrotic scar, which disrupts the normal electromechanical continuum of the ventricular muscle and compromises its pumping capacity. Recent studies in animal models of ischemic cardiomyopathy suggest that transplantation of various stem cell preparations can improve heart recovery after injury. The first clinical trials in patients produced some encouraging results, showing modest benefits. Most of the positive effects are probably because of a favorable paracrine influence of stem cells on the disease microenvironment. Stem cell therapy attenuates inflammation, reduces apoptosis of surrounding cells, induces angiogenesis, and lessens the extent of fibrosis. However, little new heart tissue is formed. The current challenge is to find ways to improve the engraftment, long-term survival and appropriate differentiation of transplanted stem cells within the cardiovascular tissue. Hence, there has been a surge of interest in pluripotent stem cells with robust cardiogenic potential, as well as in the inherent repair and regenerative mechanisms of the heart. Recent discoveries on the biology of adult stem cells could have relevance for cardiac regeneration. Here, we discuss current developments in the field of cardiac repair and regeneration, and present our ideas about the future of stem cell therapy.

show abstract

“…Intramyocardial bone marrow derived MNC transplantation with off-pump CABG led to significant improvement of 6 months LVEF and functional status compared to patients treated with surgery only. In the randomized trial of Mocini injections of bone marrow MNC into the peri-infarcted and infracted region (only patients with recent infarction were included) after the CABG during the cardiac arrest was compared to CABG alone (Mocini et al, 2006). The patient cohorts had moderate LV systolic dysfunction (inclusion criteria was baseline EF>35%).…”

Section: Transplantation Of Progenitor Cells and Recovery Of LV Functmentioning

confidence: 99%

Stem Cell Therapy in Myocardial Infarction Clinical Point of View and the Results of the REANIMA Study (REgenerAtion of Myocardium with boNe Marrow Mononuclear Cells in MyocArdial Infarction)

Obradović¹,

Balint²,

Trifunović³

2011

Stem Cells in Clinic and Research

View full text Add to dashboard Cite

Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting

Cited by 96 publications

References 26 publications

Stem Cell Therapy Combined with Myocardial Revascularization: A Pilot Study using the Harvest Technique

Stem Cell Therapy Combined with Myocardial Revascularization: A Pilot Study using the Harvest Technique

Cardiac repair and regeneration: the Rubik’s cube of cell therapy for heart disease

Stem Cell Therapy in Myocardial Infarction Clinical Point of View and the Results of the REANIMA Study (REgenerAtion of Myocardium with boNe Marrow Mononuclear Cells in MyocArdial Infarction)

Contact Info

Product

Resources

About